~~<i id='E7DC7FC6CB'><strike id='E7DC7FC6CB'><tt id='E7DC7FC6CB'><pre id='E7DC7FC6CB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：hotspot 2025-08-26 10:52:57 - browse：91

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： The response to Covid

entertainment

focus

Wikipedia

focus

leisure time

focus

AhealthcareworkerfillsasyringewithPfizer'sCovid-19vaccine.LynneSladky/APNewdatareleasedThursdaybythe

WSS

Gene therapy for Afghan refugees’ infant will be fully covered

Surgery pushed Ben Carson to fame

Top private equity targets in 2023: cardiology, clinical trials, lasers

Top private equity targets in 2023: cardiology, clinical trials, lasers

Texas Medical Board asked to define abortion emergency exception

4 missing after record

hotspot

comprehensive

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why CTE doesn’t keep Americans from enjoying the Super Bowl

How to save PrEP access — and even expand it

Statins reduce cardiovascular risk in people living with HIV

Virginia high school admissions case could be legal follow

Clinic falsely told dozens they had Alzheimer's, suits say

In age of alternative facts, a scholarly course on calling out crap

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Cancer drug shortages should be causing more outrage

Devoted Health’s losses in Medicare Advantage persist

focus

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Top private equity targets in 2023: cardiology, clinical trials, lasers

The CDC's new social media misinformation war

Why Novartis is going to walk from its acquisition of MorphoSys

What Henrietta Lacks's story taught me about my role as a doctor

The response to Covid

Wikipedia

focus

leisure time

focus